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OBJECTIVE — To evaluate whether in hypertensive patients the risk of cardiovascular dis-
ease is greater in association with the metabolic syndrome (MetS) or the sum of its individual
components.
RESEARCH DESIGN AND METHODS — Cox regression analysis models were devel-
opedtoassesstheinﬂuenceofage,sex,ethnicity,andtheindividualcomponentsofMetSonrisk
associated with the MetS (using several deﬁnitions) of coronary outcomes, stroke, and all-cause
mortality.
RESULTS — MetS was signiﬁcantly associated with coronary outcomes, stroke, and all-cause
mortality after adjusting for age, sex, and ethnicity. However, when the model was further
adjusted for the individual components, MetS was associated with signiﬁcantly increased risk of
stroke (hazard ratio 1.34 [95% CI 1.07–1.68]) and all-cause mortality (1.35 [1.16–1.58]) but
not coronary outcomes (fatal coronary heart disease plus nonfatal myocardial infarction 1.16
[0.95–1.43] and total coronary events 1.06 [0.91–1.24]).
CONCLUSIONS — MetS, independent of its individual components, is associated with
increased risk of stroke and all-cause mortality but not coronary outcomes.
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S
tudies in the recent past evaluating
the usefulness of the metabolic syn-
drome (MetS) have provided equiv-
ocal results (1–4). The database from the
blood pressure–lowering arm of the
Anglo-Scandinavian Cardiac Outcomes
Trial-Blood Pressure Lowering Arm
(ASCOT-BPLA) (5) provides an excellent
opportunity to evaluate whether in hy-
pertensive patients the risk of cardiovas-
cular (CV) disease and death is greater in
associationwiththeMetSorthesumofits
individual components.
RESEARCH DESIGN AND
METHODS— Details of the study de-
sign and methods of the ASCOT-BPLA
have been described previously (5).
Deﬁnitions
BMI30kg/m
2wasusedinsteadofwaist
circumference in deﬁning MetS because
waist circumference was not measured in
ASCOT-BPLA. The original National
Cholesterol Education Program Adult
Treatment Panel III (NCEP-ATP III) deﬁ-
nition (6) of MetS (ATP 6.1) was consid-
ered as the primary deﬁnition in these
analyses. In addition, the updated NCEP-
ATP III (ATP 5.6) (7), International Dia-
betes Federation (IDF) (8), and two other
deﬁnitions, ASCOT 6.1 and ASCOT 5.6
(modiﬁed from ATP 6.1 and ATP 5.6, re-
spectively, by excluding the “or presence
of diabetes” component from the ﬁfth cri-
terion), were also considered. The latter
two were included to reduce some of the
increased CV risk conferred by the pres-
ence of diabetes at baseline.
Outcomes
Fatal coronary heart disease (CHD) plus
nonfatal myocardial infarction (MI), total
coronary events, stroke, and all-cause
mortality were prespeciﬁed outcomes.
Statistical analyses
Three separate Cox regression analysis
models were developed for each of the
prespeciﬁed outcomes using the ATP
6.1 deﬁnition of MetS: model 1, unad-
justed MetS; model 2, adjusted for age,
sex, and ethnicity; and model 3, in-
cluded model 2 plus all the individual
components (used as continuous vari-
ables where linear) of the MetS. Risk
(hazard ratios) associated with all ﬁve
deﬁnitions of the MetS for each of the
four prespeciﬁed outcomes was com-
pared. Sensitivity assessments, which
excluded all subjects with the presence
of diabetes (or missing values) at base-
line, were done in Cox regression anal-
ysis models using the ATP 6.1 def-
inition.
RESULTS— Of 19,257 hypertensive
patients randomized in ASCOT-BPLA,
8,434 (43.8%) had the MetS based on the
ATP 6.1 deﬁnition.
MetS and rates of coronary and
stroke events and death using the
ATP 6.1 deﬁnition
In model 1, MetS was associated with a
signiﬁcantly increased risk of coronary
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ard ratio [HR] 1.24 [95% CI 1.09–
1.41], and total coronary events 1.25
[1.14–1.35]), but was not associated
with total stroke (1.07 [0.93–1.24]), or
all-cause mortality (1.07 [0.97–1.19]).
In model 2, the relationship of the MetS
with coronary outcomes became more
signiﬁcant and stronger, and it signiﬁ-
Figure 1—Different deﬁnitions of the MetS and risk of coronary, stroke, and death outcomes. A: Risk of fatal CHD (includes death from MI, acute
coronary syndrome, or sudden death attributable to ischemic heart disease) and nonfatal MI associated with MetS. B: Risk of total coronary events
(includes fatal and nonfatal CHD, unstable angina, fatal and nonfatal heart failure) associated with MetS. C: Risk of stroke associated with MetS.
D: Risk of all-cause mortality associated with MetS. Model 1: Univariate MetS. Model 2: Model 1 plus age, sex, and ethnicity. Model 3: Model 2 plus
fasting plasma glucose, triglycerides, HDL cholesterol, systolic blood pressure, and BMI.
Metabolic syndrome and cardiovascular disease risk
1648 DIABETES CARE, VOLUME 33, NUMBER 7, JULY 2010 care.diabetesjournals.orgcantly predicted total stroke (1.18
[1.02–1.36]) and all-cause mortality
(1.23 [1.11–1.35]). However, when
model 2 was further adjusted for the
individual components of the MetS
(model 3), the association between
MetS and total stroke (1.34 [1.07–
1.68]) and all-cause mortality (1.35
[1.16–1.58]) became stronger and re-
mained signiﬁcant, while the associa-
tionwithcoronaryoutcomesattenuated
and became insigniﬁcant (fatal CHD
plus nonfatal MI 1.16 [0.95–1.43] and
total coronary events 1.06 [0.91–1.24])
(see the online appendix available
at http://care.diabetesjournals.org/cgi/
content/full/dc09-2208/DC1). These re-
lationships remained unchanged on sen-
Figure 1—Continued.
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with diabetes at baseline.
Different deﬁnitions of MetS and
coronary and stroke events, and
death
The results, for each of the deﬁnitions
used, showed a consistent trend of the
MetS to signiﬁcantly predict fatal CHD
plus nonfatal MI and total coronary
eventsinmodels1and2butnotinmodel
3 (Fig. 1A and B). By contrast, the associ-
ation between the MetS, regardless of the
deﬁnition used, with stroke and all-cause
mortalitywasnotapparentinmodel1but
becameincreasinglyapparentinmodels2
and 3 such that in model 3 the results
consistently showed the MetS to be an in-
dependent predictor of total stroke and
all-cause mortality after adjusting for its
individual components (Fig. 1C and D).
CONCLUSIONS — These analyses of
19,257 hypertensive patients suggest that
theMetS,independentlyofitscomponents,
is associated with increased risk of stroke
and death but not of coronary outcomes.
The lack of any synergy among the
individualcomponentsoftheMetSonthe
risk of coronary outcomes seen in our
analyses is in keeping with ﬁndings of
some (3,4) but not all previous reports
(1,2). To compare our ﬁndings with the
studies that adjusted for classical con-
founders, we further adjusted our model
3 for confounders such as smoking, alco-
holintake,numberofCVriskfactors,and
randomized antihypertensive regimen,
but this did not change the association of
the MetS with either fatal CHD plus non-
fatalMI(HR1.10[95%CI0.90–1.35])or
total coronary events (1.01 [0.96–1.17]).
The ﬁnding of an increased risk of inci-
dent stroke associated with the MetS, inde-
pendent of its constituent components and
regardless of the deﬁnition used, extends
the ﬁndings of previous reports (9,10).
Given the potential implications of these
ﬁndings,wefurtheradjustedmodel3toin-
clude confounders such as previous history
ofstrokeortransientischemicattack,num-
berofCVriskfactors,alcoholintake,smok-
ing, history of previous antihypertensive
therapy, and randomized treatment alloca-
tion and found no change in association of
theMetSandincidentstroke(HR1.31[95%
CI 1.04–1.64]).
None of the previous studies (11,12)
have reported on the risk of death associ-
atedwiththeMetSadjustedforallitscon-
stituent components. Because in our
analyses, the MetS independently of its
components was not associated with a
signiﬁcantly increased risk of CV mortal-
ity (HR 1.19 [95% CI 0.93–1.53]), this
suggests that if the increased risk of all-
cause mortality associated with the MetS
is true, the increase must be due to
non-CV causes. Two-thirds of the 953
non-CV deaths in the ASCOT population
were due to cancer, which has previously
beenfoundtobeassociatedwiththeMetS
in observational studies (13).
TheuseofBMIinsteadofwaistcircum-
ference in our deﬁnition of the MetS is a
possible limitation of this study. However,
BMI has been used as part of previous
widely accepted studies of MetS (11,14)
and has been shown to have a comparable
predictive capability (15). The major
strength of this study is its power to exam-
ineseveralCVoutcomesandall-causemor-
talitywhileusingdifferentdeﬁnitionsofthe
MetS in the same population.
In summary, our ﬁndings suggest
that, after adjusting for its individual
components, the MetS is associated with
increased risk of strokes and all-cause
mortality but not coronary outcomes in
the hypertensive population.
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